KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Calumet (CLMT) Shares Outstanding (2022 - 2025)

Calumet (CLMT) has disclosed Shares Outstanding for 4 consecutive years, with $86.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 0.96% to $86.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $86.8 million, a 0.96% increase, with the full-year FY2025 number at $86.8 million, up 0.96% from a year prior.
  • Shares Outstanding was $86.8 million for Q4 2025 at Calumet, roughly flat from $86.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $86.8 million in Q4 2025 to a low of $79.2 million in Q4 2022.
  • A 4-year average of $83.2 million and a median of $83.1 million in 2024 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: rose 0.54% in 2024, then grew 7.98% in 2025.
  • Calumet's Shares Outstanding stood at $79.2 million in 2022, then increased by 0.98% to $80.0 million in 2023, then rose by 7.48% to $86.0 million in 2024, then grew by 0.96% to $86.8 million in 2025.
  • Per Business Quant, the three most recent readings for CLMT's Shares Outstanding are $86.8 million (Q4 2025), $86.8 million (Q3 2025), and $86.7 million (Q2 2025).